GPP
FULC icon

Great Point Partners’s Fulcrum Therapeutics FULC Stock Holding History

Great Point Partners’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-800,000
Closed -$9.05M – 44
2025
Q4 		$9.05M Buy
+800,000
New +$8.14M 2.93% 14

Other funds holding FULC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
FTM
First Turn Management Del Mar, California $895M AUM 261.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Great Point Partners's FULC Position: Q1 2026 in Review

Great Point Partners sold out of Fulcrum Therapeutics (FULC) in Q1 2026, closing a stake of 800,000 shares — an estimated $9.05M sold.

Great Point Partners first reported a position in FULC in Q4 2025 and held it in 1 quarter. The position peaked at $9.05M in Q4 2025. 169 funds tracked by Wall St. Rank hold FULC as of Q1 2026.

  • Great Point Partners reported no remaining Fulcrum Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Great Point Partners sold 800,000 Fulcrum Therapeutics shares in Q1 2026, an estimated $9.05M.
  • Great Point Partners first reported a position in Fulcrum Therapeutics in Q4 2025 and held it in 1 quarter.
  • Great Point Partners's Fulcrum Therapeutics position peaked at $9.05M in Q4 2025.
  • 169 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2026.

Based on Great Point Partners's 13F filing for Q1 2026, filed 15 May 2026.